import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "how-much-does-foxo4-dri-cost-research-pricing-guide",
  title: "How Much Does FOXO4-DRI Cost? Research Pricing Guide (2026)",
  description:
    "A breakdown of FOXO4-DRI pricing in 2026 — typical vial costs, why D-retro-inverso peptides cost more, what to look for in quality documentation, and how it compares to other senolytic research compounds.",
  category: "Research Fundamentals",
  readMinutes: 7,
  publishedAt: "2026-06-20",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "FOXO4-DRI is a D-retro-inverso peptide designed to interfere with the interaction between FOXO4 and p53, the molecular mechanism by which senescent cells resist apoptosis. It was the subject of a widely-cited 2017 Nature Medicine paper by Baar et al. demonstrating elimination of senescent cells in mouse models with apparent improvements in fur density, physical fitness, and renal function. That study catalyzed significant research interest in senolytic peptides, and FOXO4-DRI has become a benchmark compound for cellular senescence research — but its structural class makes it among the more expensive peptides per milligram.",
    },
    {
      type: "heading",
      text: "Typical FOXO4-DRI Pricing in 2026",
    },
    {
      type: "paragraph",
      text: "FOXO4-DRI is expensive per milligram relative to natural L-amino acid peptides of similar length. This reflects the significant overhead of D-amino acid SPPS and the retro-inverso synthesis approach.",
    },
    {
      type: "table",
      headers: ["Vial Size", "Typical Price Range", "Cost per mg (midpoint)", "Common Use Case"],
      rows: [
        ["1 mg", "$60–$100", "~$80/mg", "Pilot in vitro senescence assay"],
        ["2 mg", "$110–$175", "~$71/mg", "Small animal study, short-duration"],
        ["5 mg", "$220–$380", "~$60/mg", "Standard research vial for in vivo work"],
        ["10 mg", "$380–$650", "~$51/mg", "Multi-experiment protocol"],
      ],
    },
    {
      type: "paragraph",
      text: "These figures reflect vendors with accessible, batch-specific analytical documentation. The market for FOXO4-DRI includes a meaningful number of lower-quality suppliers whose pricing may be 40–60% below this range — pricing that almost invariably reflects absent or insufficient testing.",
    },
    {
      type: "heading",
      text: "Why FOXO4-DRI Is More Expensive Than Standard Peptides",
    },
    {
      type: "subheading",
      text: "D-Amino Acid Synthesis",
    },
    {
      type: "paragraph",
      text: "Standard peptide synthesis uses L-amino acids, which are the naturally occurring forms. D-amino acids — their mirror-image counterparts — require separate, dedicated Fmoc-protected building blocks that are significantly more expensive than their L-form equivalents. For a 34-amino acid peptide where every residue is D-configured (as in a full D-retro-inverso compound), raw material costs can be 4–8x higher than for the equivalent L-peptide sequence.",
    },
    {
      type: "subheading",
      text: "Retro-Inverso Design",
    },
    {
      type: "paragraph",
      text: "The 'retro-inverso' designation means that not only is the peptide composed of D-amino acids, but the sequence is also reversed relative to the natural L-peptide target sequence. This design is intended to mimic the shape of the natural L-peptide binding surface while being resistant to proteolytic degradation — a key feature for in vivo research where natural peptides are rapidly cleared. The synthesis requires careful verification that the correct reversed sequence has been assembled, adding QC complexity.",
    },
    {
      type: "subheading",
      text: "Analytical Verification Complexity",
    },
    {
      type: "paragraph",
      text: "Verifying a D-retro-inverso peptide requires more than a standard HPLC purity check. Mass spectrometry must confirm the correct molecular weight. Additionally, chiral purity analysis — confirming that the amino acids are actually in the D-configuration rather than L — requires specialized methods such as amino acid analysis after hydrolysis and chiral separation. Vendors performing full characterization carry higher QC costs.",
    },
    {
      type: "subheading",
      text: "Lower Synthesis Scale",
    },
    {
      type: "paragraph",
      text: "FOXO4-DRI has a more specialized research demand than common peptides like BPC-157 or ipamorelin. Smaller synthesis scale means higher per-unit costs before testing — the economics of scale that reduce the per-mg cost of high-volume compounds do not apply to the same degree.",
    },
    {
      type: "heading",
      text: "FOXO4-DRI vs. Other Senolytic Research Compounds",
    },
    {
      type: "table",
      headers: ["Compound", "Typical 5 mg Price", "Mechanism", "Structural Class"],
      rows: [
        ["FOXO4-DRI", "$220–$380", "FOXO4/p53 interaction inhibitor", "D-retro-inverso peptide"],
        ["GHK-Cu", "$30–$55", "Copper complex, gene expression modulation", "Tripeptide + copper"],
        ["Epitalon", "$35–$65", "Telomerase activation via pineal regulation", "Natural tetrapeptide"],
        ["SS-31 (Elamipretide)", "$80–$140", "Mitochondrial membrane targeting", "D-arg-containing tetrapeptide"],
        ["NAD+ (direct)", "$40–$80 (50 mg)", "Sirtuin/PARP substrate", "Dinucleotide (non-peptide)"],
      ],
    },
    {
      type: "paragraph",
      text: "FOXO4-DRI is the most expensive common senolytic research compound per milligram, reflecting its D-retro-inverso chemistry. Epitalon and GHK-Cu offer longevity-axis research at much lower cost per milligram, albeit through different mechanisms.",
    },
    {
      type: "heading",
      text: "Critical Quality Checks for FOXO4-DRI",
    },
    {
      type: "paragraph",
      text: "Given the synthesis complexity and the importance of D-amino acid configuration for the intended mechanism, quality verification is particularly important for FOXO4-DRI:",
    },
    {
      type: "list",
      items: [
        "HPLC purity ≥95% (some vendors achieve ≥98% — this is preferable for in vivo use)",
        "Mass spectrometry confirming the correct molecular weight (FOXO4-DRI is approximately 3,853 Da for the 34 AA D-retro-inverso peptide)",
        "Evidence of D-amino acid source — vendor should specify D-Fmoc amino acid suppliers or confirm chiral configuration",
        "Endotoxin (LAL) test result if the compound will be used in animal models",
        "Lot number on COA matching vial label",
        "Reconstitution guidance (FOXO4-DRI typically requires DMSO for initial dissolution, then aqueous dilution)",
      ],
    },
    {
      type: "paragraph",
      text: "The last point — reconstitution — is practically important for researchers. FOXO4-DRI is poorly water-soluble and typically requires dissolution in DMSO (dimethyl sulfoxide) to a stock concentration of 5–10 mg/mL, followed by dilution in sterile saline or PBS. Vendors who provide reconstitution guidance alongside QC documentation are demonstrating hands-on familiarity with the compound.",
    },
    {
      type: "heading",
      text: "What Low Prices Signal for FOXO4-DRI",
    },
    {
      type: "paragraph",
      text: "For most research peptides, unusually low pricing suggests insufficient testing. For FOXO4-DRI specifically, very low pricing may additionally indicate that the vendor is selling an L-amino acid version of the peptide sequence rather than the D-retro-inverso form — which is far cheaper to produce, looks identical on basic HPLC, and has essentially no proteolytic stability or cellular activity relative to the authentic compound. Without amino acid analysis or chiral separation data, a researcher has no way to confirm they have received the actual D-configured compound.",
    },
    {
      type: "paragraph",
      text: "This risk is not hypothetical. The D-retro-inverso synthesis premium is large enough that the financial incentive to substitute an L-peptide is real for suppliers willing to cut corners.",
    },
    {
      type: "heading",
      text: "Research Applications Driving Demand",
    },
    {
      type: "paragraph",
      text: "Research interest in FOXO4-DRI is concentrated in three areas: (1) cellular senescence mechanistic studies examining FOXO4/p53 axis biology; (2) preclinical models of age-related pathology where senescent cell burden is an endpoint; and (3) combination senolytic protocols studied alongside compounds like Epitalon, NAD+, and GHK-Cu. The 2017 Baar et al. paper established a research framework that subsequent groups have extended into models of fibrosis, neurodegeneration, and metabolic dysfunction.",
    },
    {
      type: "heading",
      text: "Where Nexphoria Fits",
    },
    {
      type: "paragraph",
      text: "Nexphoria stocks FOXO4-DRI with batch-specific analytical documentation including HPLC and mass spectrometry. Pricing reflects the legitimate cost of D-amino acid synthesis and thorough analytical verification. Researchers using FOXO4-DRI for senescence work can expect documentation that supports their experimental record.",
    },
    {
      type: "callout",
      text: "FOXO4-DRI is sold for research purposes only. It is not approved for human use. Researchers should follow all applicable institutional and regulatory guidelines.",
    },
    {
      type: "disclaimer",
      text: "Pricing data reflects market survey information as of mid-2026 and may change. This article is for informational purposes and does not constitute a price guarantee or competitive comparison.",
    },
  ],
};
